Plozasiran is another apoC-III inhibitor that showed the potential to reduce TG levels in patients with mixed hyperlipidemia and the risk of acute pancreatitis in patients with sHTG [73,74,75]. This evidence concerns the gene APOC3 and acute pancreatitis.